Research and Markets: OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024

Research and Markets has announced the addition of the "OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024" report to their offering.

OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024 estimates the 2014 sales for the Fabry disease market at approximately $682m across the 7MM.

The US contributed the majority of these sales, generating an estimated $295m. By the end of the forecast period in 2024, Fabry disease sales are expected to grow to $1.25 billion at a Compound Annual Growth Rate (CAGR) of 6.3% over the 10-year period. The majority of sales in the 7MM in 2024 will come from the US, which will represent 44.2% of the market.

GlobalData expects an increase in the number of newly diagnosed cases of Fabry disease, and consequently in the number of treatable Fabry patients, as a result of increasing awareness of Fabry disease among physicians. ERT is now well established in the treatment of Fabry disease; however, there still remains concern about its efficacy, tissue penetrance, and intravenous administration. As a result, alternative approaches are being investigated to advance new treatments for Fabry disease, which focus on three main areas of research: chaperone therapies, substrate reduction therapies (SRTs), and combinations of their use with ERT.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Current Treatment Options

6 Unmet Needs Assessment and Opportunity Analysis

7 Research and Development Strategies

8 Pipeline Assessment

9 Pipeline Valuation Analysis

10 Appendix

Companies Mentioned

• Genzyme
• Shire
• Amicus Therapeutics
• Sanofi

For more information visit http://www.researchandmarkets.com/research/4rh65t/opportunityanalyze

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005290/en/